MAXIGRATAN 150 Capsules

Description

Dabigatran Etexilate

• Drug class: Direct thrombin inhibitors
• Benefits of DES (Dabigatran Etexilate Mesylate) include a fast onset and offset of action, a relatively short half-life, and limited drug-drug interaction.
• Demonstrates superiority over enoxaparin in the treatment of venous embolism afteorthopedicic surgery.
• Clinical trials have proven that it is more efficacious than warfarin and does not require any coagulation monitoring.
• Also prevents and treats recurring blood clots in veins of legs and lungs.
• Dabigatran etexilate mesylate is an outstanding anticoagulant, beneficial in the treatment of stroke and systemic embolism.
• Effective in the treatment of deep vein thrombosis, Pulmonary embolism, recurrent pulmonary embolism, and Non-valvular atrial fibrillation.’
• Also used for the prevention of venous thromboembolic events in patients with recent elective hip or knee replacement surgery and atrial fibrillation.